IRVING, Texas, Aug 19, 2004 -- Carrington Laboratories, Inc., (CARN) announced today that Humayoun Akhter, Ph.D., will lead Carrington's new product development efforts as Director, Research and Development. Dr. Akhter will specialize in new and innovative formulations for personal care and OTC monograph drug products for the consumer markets. His efforts will support Carrington's specialty manufacturing business which private-labels products for other retailers or mass merchandisers, as well as bolster the company's own growing line of skin care, health maintenance and wound care products sold under its AloeCeuticals(R) and Carrasyn(R) brands.
Dr. Akhter most recently was general manager of research and development for ETS, Inc. of Indianapolis, Indiana. Prior to that, he was manager of the Radical Innovations Laboratory of Avlon Industries in Chicago. Over the past seven years, Dr. Akhter has developed over 80 new and innovative products for hair and skin care, including sunscreens, sunless tanning and moisturizing products, and anti-aging and skin-firming creams and lotions. He earned his Ph.D. in organic chemistry, with a minor in analytical chemistry, at Louisiana State University. Dr. Akhter has authored over a dozen published scientific papers, and currently serves as a reviewer of scientific papers for the "Journal of Cosmetic Science." He is a member of the Society of Cosmetic Chemists, the American Chemical Society and the Phi Lambda Upsilon Honorary Chemical Society.
Carlton E. Turner, Ph.D., D.Sc., president and CEO of Carrington, stated, "Dr. Akhter has established a reputation for developing cutting edge products. We believe that his knowledge and expertise, combined with our proprietary raw materials and technology, will yield a multitude of new products that will appeal to a multitude of customers serviced by our specialty manufacturing group."
Carrington Laboratories, Inc., is an ISO 9001-certified, research-based biopharmaceutical and consumer products company currently utilizing naturally- occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products under the AloeCeuticals(R) brand and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. The Company's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(TM) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 120 patents in 26 countries. Select products are honored with the internationally coveted CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com .
Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10Q filed August 13, 2004.
Carrington, Manapol, AloeCeuticals, Hydrapol, GelSite, GelVac and Acemannan Hydrogel are trademarks, registered trademarks or service marks of Carrington Laboratories, Inc., in the United States and other countries. All other trademarks or service marks contained herein are the properties of their respective owners.